ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

13 2 2025 16:01:00 提供 Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update

06 2 2025 16:30:00 提供 Nasdaq GlobeNewswire

Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS

05 2 2025 08:00:00 提供 Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

17 1 2025 16:30:00 提供 Nasdaq GlobeNewswire

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones

12 1 2025 11:00:00 提供 Nasdaq GlobeNewswire

Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

06 1 2025 16:30:00 提供 Nasdaq GlobeNewswire

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

06 1 2025 02:00:43 提供 Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

20 12 2024 16:30:00 提供 Nasdaq GlobeNewswire

Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome

19 12 2024 16:05:00 提供 Nasdaq GlobeNewswire

Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)

19 12 2024 08:00:00 提供 Nasdaq GlobeNewswire

Ultragenyx to Participate in Investor Conferences in December

26 11 2024 16:30:00 提供 Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

20 11 2024 16:30:00 提供 Nasdaq GlobeNewswire

Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit

09 11 2024 10:30:00 提供 Nasdaq GlobeNewswire

Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update

05 11 2024 16:01:00 提供 Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update

29 10 2024 16:05:00 提供 Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

18 10 2024 16:30:00 提供 Nasdaq GlobeNewswire

Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta

07 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

03 10 2024 16:30:00 提供 Nasdaq GlobeNewswire

Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting

26 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

18 9 2024 17:00:00 提供 Nasdaq GlobeNewswire